End‐stage renal disease as an independent risk factor for in‐hospital mortality after coronary drug‐eluting stenting: Understanding and modeling the risk

2020 ◽  
Author(s):  
Aaron N. Dunn ◽  
Chetan Huded ◽  
Conrad Simpfendorfer ◽  
Russell Raymond ◽  
Samir Kapadia ◽  
...  
Keyword(s):  
Risk Factor ◽  
Renal Disease ◽  
Hospital Mortality ◽  
End Stage Renal Disease ◽  
Independent Risk Factor ◽  
Drug Eluting ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals FP679VITAMIN D DEFICIENCY IS AN INDEPENDENT RISK FACTOR FOR ANEMIA IN PATIENTS WITH END-STAGE RENAL DISEASE

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii301-iii301
Author(s):  
In Mee Han ◽  
Ryu Geun Woo ◽  
Jong Hyun Jhee ◽  
Hyung Woo Kim ◽  
Sul A Lee ◽  
...  
Keyword(s):  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Independent Risk Factor ◽  
Stage Renal Disease ◽  
End Stage

Abstract 282: In Hospital Outcomes of Cardiac Arrest in Patient with End Stage Renal Disease

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_4) ◽  
Author(s):  
Muhammad Khan ◽  
Muhammad U Khan ◽  
Muhammad Munir
Keyword(s):  
Cardiac Arrest ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
International Classification ◽  
International Classification Of Disease ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End stage renal disease (ESRD) is a well-recognized risk factor for development of sudden cardiac arrest(SCA). There is limited data on outcomes after an in-hospital SCA event in ESRD patients. Methods: Data were obtained from National Inpatient Sample from January 2007 to December 2017. In-hospital SCA was identified using International Classification of Disease, 9th Revision, Clinical Modification, and International Classification of Disease, 10th Revision, Clinical Modification codes of 99.60, 99.63, and 5A12012. ESRD patients were subsequently identified using codes of 585.6 and N18.6. Propensity -matched analysis using logistic regression with SD caliper of 0.2 was used to match patients with and without ESRD. Crude and propensity-matched (PS) cohorts outcomes were calculated. Results: A total of 1,412,985 patients sustained in-hospital SCA during our study period. ESRD patients with in-hospital SCA were younger and had a higher burden of key co-morbidities. Mortality was similar in ESRD and non-ESRD patients in PS matched cohort (70.4% vs. 70.7%, p = 0.45, figure 1) with an overall downward trend over our study years (figure 2). Conclusion: In the context of in-hospital SCA, mortality is similar in ESRD and non-ESRD patients in adjusted analysis. Adequate risk factor modification could further mitigate the risk of in-hospital SCA among ESRD patients

Drug-eluting compared to bare metal stents in patients with end-stage renal disease on dialysis

2019 ◽  
Vol 20 (5) ◽  
pp. 313-320 ◽  
Author(s):  
Vincenzo Alessandro Galiffa ◽  
Gabriele Crimi ◽  
Valeria Gritti ◽  
Valeria Scotti ◽  
Maurizio Ferrario ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Bare Metal Stents ◽  
Metal Stents ◽  
Bare Metal ◽  
Drug Eluting ◽  
Stage Renal Disease ◽  
End Stage

Assessing Plasma Total Homocysteine in Patients with End-Stage Renal Disease

2007 ◽  
Vol 27 (5) ◽  
pp. 476-488 ◽  
Author(s):  
Bradley L. Urquhart ◽  
Andrew A. House
Keyword(s):  
Cardiovascular Disease ◽  
Risk Factor ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Elevated Plasma ◽  
Plasma Thcy ◽  
Total Homocysteine ◽  
Stage Renal Disease ◽  
End Stage ◽  
Plasma Total Homocysteine

Elevated plasma total homocysteine (tHcy) is a risk factor for cardiovascular disease; however, in light of several recent randomized trials, the issue of causality has been cast into doubt. Patients with end-stage renal disease are particularly interesting as they consistently have elevated tHcy and their leading causes of morbidity and mortality are related to cardiovascular disease. In the present article, we review the early evidence for the homocysteine theory of atherosclerosis, homocysteine metabolism, mechanisms of toxicity, and pertinent available clinical investigations. Where appropriate, the sparse evidence of homocysteine in peritoneal dialysis is reviewed. We conclude by addressing the difficulties associated with lowering plasma tHcy in patients with end-stage renal disease and suggest some novel methods for lowering tHcy in this resistant population. Finally, to address the issue of causality, we recommend that clinicians and scientists await the results of the FAVORIT trial before abandoning homocysteine as a modifiable risk factor for cardiovascular disease, as this study has recruited patients from a population with consistently elevated plasma tHcy who are known to respond to vitamin therapy.

scholarly journals The Impact of Warfarin on Patients with End Stage Renal Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Anahita Dua ◽  
Sapan S. Desai ◽  
Harvey J. Woehlck ◽  
Cheong J. Lee
Keyword(s):  
Renal Disease ◽  
Hospital Mortality ◽  
End Stage Renal Disease ◽  
Hospital Charges ◽  
Care Utilization ◽  
Chronic Obstructive ◽  
Chronic Obstructive Pulmonary Disorder ◽  
Stage Renal Disease ◽  
End Stage ◽  
The Impact

Introduction. A deficiency in vitamin K through the utilization of warfarin may result in increased vascular calcification and complications. This study aimed to determine the impact of warfarin administration on patients with end stage renal disease (ESRD) in a large, national sample. Methods. A retrospective analysis using the 2005–2010 National Inpatient Sample (NIS), a part of the Health Care Utilization Project (HCUP), was completed using ICD-9 diagnosis codes to capture patients with ESRD prescribed and not prescribed warfarin. Statistical analysis was through ANOVA and chi-squared testing. Results. From 2005–2010, 927,814 patients with ESRD were identified nationally. 3.5% (32,737) were prescribed warfarin. Patients prescribed warfarin had an average age of 64 years and 51% were male. For every comorbid condition (amputation, congestive heart failure, chronic obstructive pulmonary disorder, cerebrovascular accident, diabetes, hypertension, myocardial infarction, peripheral vascular diasese, and valvular disease) patients prescribed Warfarin had significantly higher rates of disease as compared to their nonwarfarin ESRD counterparts. ESRD patients prescribed warfarin had significantly shorter length of stay but increased hospital charges. They were more likely to be discharged to home and had significantly decreased in-hospital mortality. Conclusion. Patients with ESRD taking warfarin are more likely to have comorbidities and/or complications but have a decreased LOS and in-hospital mortality compared to their ESRD counterparts not administered warfarin.

Sign in / Sign up

Export Citation Format

Share Document